Cara Therapeutics, Inc. (CARA)

0.6843 -0.0157 (-2.24%) 收市：04:00PM EDT

Cara Therapeutics, Inc.

400 Atlantic Street
Suite 500
Stamford, CT 06901
United States
203 406 3700
https://www.caratherapeutics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 55

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Christopher A. Posner	President, CEO & Director	1.15M	無	1970
Mr. Ryan D. Maynard	Chief Financial Officer	670.7k	無	1969
Dr. Derek T. Chalmers D.Sc., Ph.D.	Co-Founder & Senior Advisor	580.93k	無	1964
Dr. Iris Francesconi Ph.D.	Chief Strategy Officer & Head of Investor Relations	無	無	無
Mr. Scott M. Terrillion	Chief Compliance Officer, General Counsel & Corporate Secretary	689.63k	無	1963
Ms. Beth Weinberg R.Ph.	Senior Vice President of Regulatory Affairs & QA	無	無	無
Mr. Matthew Murphy	Manager of Investor Relations	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

公司管治

截至 2024年4月1日 止，Cara Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：4；董事會：4；股東權利：7；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。